Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.”
Email: jackfriday2011(at)hotmail.co.uk
Friday, July 04, 2008
Insider hears.....
Pfizer is working on a counter offer that will be 20% higher than the price offered by Japan's Daiichi Sankyo to buy a majority stake in Indian drugmaker Ranbaxy.
2 comments:
Anonymous
said...
I think its only just that after running a major part of pharma discovery in US and UK into the ground, Pfizer now moves to do the same to India. And they always convince their shareholders that their next move is a great way "to maximise the shareholder's value in this current difficult business environment". Look at the health of Pfizer stock over the last decade - there's a quack remedy at work.
It makes sense given the fact that if they do this, they'll be able to salvage some Lipitor dollars. However, I'm a bit skeptical considering the 2 companies just settled on Lipitor to begin with.
2 comments:
I think its only just that after running a major part of pharma discovery in US and UK into the ground, Pfizer now moves to do the same to India. And they always convince their shareholders that their next move is a great way "to maximise the shareholder's value in this current difficult business environment". Look at the health of Pfizer stock over the last decade - there's a quack remedy at work.
It makes sense given the fact that if they do this, they'll be able to salvage some Lipitor dollars. However, I'm a bit skeptical considering the 2 companies just settled on Lipitor to begin with.
Post a Comment